Industry News
Pharmaceutical Industry News
F.D.A. Authorizes a New Covid Drug to Protect High-Risk People
Pemgarda, available in the coming weeks, is intended for immunocompromised people who are unlikely to mount an adequate response after vaccination.
A Complete Guide to Allergy Treatments for Your Symptoms
You’re sniffling, sneezing and staring at the pharmacy shelf. Here’s how to choose the right option for your symptoms.
Patients Hate ‘Forever’ Drugs. Are Ozempic and Wegovy Different?
The new obesity drugs might be an exception to a chronic, deadly problem: the failure to stick with medication.
The Psychedelic Evangelist
A Johns Hopkins scientist was known for rigorous studies of psychedelics. Was he a true believer?
Centene Health Care Fraud Case: How Private Lawyers Profited
A group of politically connected lawyers teamed up to go after insurers and made millions from one of the largest Medicaid settlements in history.
A Psychedelics Reporter With a Changing Perspective
Can an experimental drug cure opioid addiction? Andrew Jacobs, who writes about psychedelic medicine for The Times, explored the “promise and peril” of ibogaine.
The High Cost of Weight-Loss Drugs
Readers discuss the costs and benefits. Also: Donald Trump’s remark about American Jews and Israel; subway shootings; abortion providers; FAFSA chaos.
‘What’s My Life Worth?’ The Big Business of Denying Medical Care
Insurance companies have weaponized a seemingly benign process to protect their profits, and it’s putting patients at risk.
Oregon Decriminalized Drugs. Voters Now Regret It.
State lawmakers are about to reverse course, making the possession of hard narcotics an offense again.
The Challenges of Teaching Constitutional Law Today
Readers discuss an Opinion piece about a politicized Supreme Court. Also: Trump’s mockery of Biden; fans of the president; alcoholism; great literature.
Lo que hay que saber sobre la ibogaína
Algunos investigadores esperan que la droga, aún ilegal en Estados Unidos, pueda considerarse como tratamiento para la adicción, el trastorno de estrés postraumático y las lesiones cerebrales.
With Cyberattack Fix Weeks Away, Health Providers Slam United
Hospitals, doctors and clinics expressed frustration that they will have to wait even longer for reimbursements after hackers paralyzed the largest U.S. billing clearinghouse.
A.L.S. Drug Relyvrio Fails Clinical Trial and May Be Withdrawn From the Market
Leaders of the treatment’s manufacturer, Amylyx, said they would announce their plans for it within eight weeks.
F.D.A. Delays Action on Closely Watched Alzheimer’s Drug
Eli Lilly’s donanemab was expected to be approved this month, but the agency has decided to convene a panel of independent experts to evaluate the drug’s safety and efficacy.
¿Se puede tener alzhéimer y no presentar síntomas?
Una propuesta para cambiar los lineamientos de detección de la enfermedad podría tener un gran impacto en la cantidad de casos diagnosticados.
Cyberattack Paralyzes the Largest US Health Care Payment System
The hacking shut down the nation’s biggest health care payment system, causing financial chaos that affected a broad spectrum ranging from large hospitals to single-doctor practices.
Powerful Psychedelic Drug Gains New Notice as an Opioid Addiction Therapy
New research is stirring interest in ibogaine, which appears to help ease the agony of detox and prevent relapse. Used in other countries, it remains illegal in the U.S.
What to Know About Ibogaine, a Psychedelic
Some researchers hope the drug, still illegal in the United States, may be considered as a treatment for addiction, PTSD and brain injuries.
Opill, an Over-the-Counter Birth Control Pill, Will Be Available Soon
Opill will cost $19.99 per month or $49.99 for a three-month supply.
Apparently Healthy, but Diagnosed With Alzheimer’s?
New criteria could lead to a dementia diagnosis on the basis of a simple blood test, even in the absence of obvious symptoms.